From July 1st to August 31st, 2024, take advantage of exceptional savings on our hematopoietic cell products: PBMC, MNC-CB, and CD34+ Hematopoietic Progenitors. Contact us at commercial@abcell-bio.com for more information.

Abcell-bio arose from the will to accompany research by facilitating the access to primary resources which are difficult to get, especially cells from cord blood.

With a strong and unique network of French maternities and a robust production process, Abcell-bio also develops a Research & Development activity to face the challenges of the upcoming research.

Every year, we hear about Pink October and Movember, but Red September isn’t as widely recognized. This month is dedicated to raising awareness for blood cancers, which affect 45,000 individuals annually in France. ‘Live with a MPN’, a patient association, launched this initiative last year and is now rolling out its second edition.

This article describe a new humanized mice model that is a unique tool for investigating, in vivo, the biology of Plasmodium vivax, the most widespread human malaria parasite. This new model of humanized mice using CD34+ cells from cord blood (purchased from Abcell-bio company), allows a reconstitution of the human erythropoiesis.

Although umbilical cord blood (UCB) is a promising source of Hematopoietic stem and progenitor cells (HSPCs), the low dose of HSPCs in these preparations limits their use, prompting need for ex vivo HSPC expansion. This study reports the development of a bioactive peptide named SL-13R, the design of which was originally derived from sequence of the extracellular domain of Delta-like homologue 1 (DLK1) protein, expressed on hepatoblasts. UCB HSPCs were cultured with SL-13R in combination with hematopoietic cytokines under xeno-free conditions. SL-13R enhanced ex vivo expansion of UCB HSPCs without loss of long-term reconstitution ability. Transplantation of cells cultured with SL-13R into immunodeficient NOD/Shi-scid/IL-2R knockout mice confirmed that they possess long-term reconstitution and self-renewal abilities. As the specialist in the production of hematopoietic progenitors, Abcell-bio is able to provide large quantities of CD34+ cells from a single healthy donor, certifying their purity and viability. Nii T, Konno K, Matsumoto M, Bhukhai K, Borwornpinyo S, Sakai

This article describe a new humanized mice model that is a unique tool for investigating, in vivo, the biology of Plasmodium vivax, the most widespread human malaria parasite. This new model of humanized mice using CD34+ cells from cord blood (purchased from Abcell-bio company), allows a reconstitution of the human erythropoiesis. Conclusion: This model holds promise for understanding in vivo host-parasite interactions and could offer a unique opportunity for in vivo testing of novel antimalarial interventions. Luiza-Batista C, et al. Humanized mice for investigating sustained Plasmodium vivax blood-stage infections and transmission. Nat Commun. 2022 Jul 15;13(1):4123. doi: 10.1038/s41467-022-31864-6.

This study aims at investigating the co-implantation of human adipose-derived stem cells (ADSCs) after osteogenic differentiation and human umbilical vein endothelial cells (HUVECs) embedded in a vascularized osteogenic matrix of hydroxyapatite (HAp) ceramic for bone tissue engineering. Interestingly, the implantation of HUVEC led to bone formation, suggesting that implanted HUVEC stimulated bone formation. This result may be caused the ability of the extracellular matrix from HUVEC to stimulate the osteogenic differentiation of osteoprogenitor cells. The implantation of osteogenically differentiated ADSC led to higher bone formation than the implantation of HUVEC. But only the co-implantation of ADSC and HUVEC led to a statistically significant larger bone area compared to the other cell-containing groups. This supports the results of earlier studies which showed that endothelial cells stimulate proliferation, cell survival and osteogenic differentiation of osteoprogenitor cells in vitro and bone formation in vivo. Hence, the co-implantation of differentiated ADSCs with HUVECs may therefore be considered

Biotechnology laboratory, Abcell-bio produces quality primary human cells from perinatal tissues. Our team is made up of dedicated scientists, whose objective is to facilitate the R&D work of our customers by forging real partnerships. As such, Abcell-bio is now part of the France Biotech network, whose role is to federate HealthTechs and MedTechs companies in France. The objective is to develop partnerships, private or public, in order to be more and more a player in the ecosystem of health innovation! Would you like to develop a research partnership? Contact us, the scientific team will be delighted to answer your questions and support you in your projects.

Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSCs). Comparatively, UCB HSCs have an extensive proliferative capacity that exceeds that of bone marrow HSCs. However, the small quantity of HSCs obtained from an umbilical cord remains a problematic element restricting the usage of UCB and the quality of UCB units has to be checked before cryopreservation. This study aimed to determine the maternal and neonatal factors that influence UCB before selection for cryopreservation. The analysis included 403 processed UCB units. Neonates with higher birth weights produced better quality UCB units because of increased collected blood volumes, total nucleated cell counts, and CD34+ cell counts. However, an increase in the gestational age from 35 to 41 weeks led to decreases in the collected blood volume and CD34+ cell count. As the specialist in the production of CD34+ progenitors from cord blood, Abcell-bio controls the collection and the selection